TROPION-Lung01 Presents Further Data on Dato-DXd for NSCLC at WCLC – ASCO

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“Lung Cancer Study (TROPION-Lung01) Presents Further Data on Dato-DXd for NSCLC at WCLC Today.

The phase III TROPION-Lung01 study presented additional data today at the IASLC 2024 World Conference on Lung Cancer in San Diego. The study evaluated Datopotamab Deruxtecan (Dato-DXd) as a potential new second-line treatment option for patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC).

Key findings include:

• Improved PFS: 4.4 months with Dato-DXd versus 3.7 months with docetaxel. Particularly strong results were observed in patients with non-squamous histology.
• Reduced severe adverse effects:Dato-DXd had fewer high-grade adverse events compared to docetaxel.
• Benefit in overall survival: The study also showed a numeriNumericalcal benefit in overall survival, although this did not reach statistical significance.

The full results are published in our Journal of Clinical Oncology.

Read more in ASCO Daily News.”

Source: ASCO/LinkedIn

More posts featuring ASCO on oncodaily.com

The American Society of Clinical Oncology (ASCO) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.